Prelude therapeutics and abcellera enter partnership to develop first-in-class precision antibody drug conjugates in oncology

Wilmington, del. & vancouver, british columbia--(business wire)---- $abcl--prelude therapeutics and abcellera enter partnership to develop first-in-class precision antibody drug conjugates in oncology.

ABCL Ratings Summary

ABCL Quant Ranking